lisa_labSD said:

503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously: Feature 503A 503B Regulation State Board of Pharmacy…

Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.

Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide still in shortage, tirzepatide removed from shortage list. This directly impacts compounding availability.

The figures, for anyone assembling their own picture. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

I would rather be corrected than agreed with, if it comes to it.

A narrower follow-up, since the general answer is now clear:

Was that from a primary source or from a summary of one?

dan_philly said:

One habit that pays for itself: post the method alongside the number.

I read this differently from dan_philly, on substance rather than tone. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

dan_philly said:

One habit that pays for itself: post the method alongside the number.

No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.